PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer.

CONCLUSIONS: Targeting two IFNg-inducible, tumor-associated antigens - ICAM1 and PD-L1 - in a complementary manner might be an effective treatment strategy to control advanced thyroid cancers in vivo.
PMID: 32887724 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 3, 2020 Category: Cancer & Oncology Authors: Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, El Eshaky S, Yang Y, Shevlin E, Zaman M, Ullmann TM, Liang H, Stefanova D, Christos PJ, Scognamiglio T, Tassler AB, Zarnegar R, Fahey TJ, Jin MM, Min IM Tags: Clin Cancer Res Source Type: research